SPRB SPRUCE BIOSCIENCES, INC.

NEUTRAL Impact: 5/10 424B5
Horizon weeks Filed Apr 20, 2026 Processed 1mo ago SEC 0001193125-26-163919
Notable filing: 424B5
Latest settled — T+20d
SPRB ▼ -0.54% at T+20d
NEUTRAL call ✗ call lost -0.54% · α vs SPY -5.46% · entry $51.69 → $51.41
Next anchor: T+60d in 5w
Currently $51.89 · +0.39% from $51.69 entry
Entry anchored
Apr 20, 03:59 PM ET
via Databento tick
T+1d
+1.30%
call +1.30% · α +0.28%
$52.36
settled 8w ago
T+5d
+5.96%
call +5.96% · α +4.87%
$54.77
settled 7w ago
T+20d
-0.54%
call -0.54% · α -5.46%
$51.41
settled 26d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Spruce Biosciences is conducting a public offering of common stock and pre-funded warrants to raise capital, with net proceeds intended for advancing pre-commercial activities, clinical trials, and general corporate purposes. The offering includes an over-allotment option and is subject to a 90-day lock-up agreement for insiders. The pre-funded warrants have a nominal $0.01 exercise price and will not generate meaningful proceeds upon exercise.

Actionable Insight

Monitor the final pricing and size of the offering when announced, as this will determine the actual dilution impact. Watch for any updates on the company's clinical trial progress and cash runway extension, which will be key indicators of how effectively the raised capital is being deployed.

Key Facts

  • Offering includes common stock and pre-funded warrants with a $0.01 exercise price
  • Net proceeds will fund pre-commercial activities, clinical trials, and general corporate purposes
  • 90-day lock-up agreement for officers, directors, and certain stockholders
  • No established market for pre-funded warrants; liquidity will be limited
  • Company will receive only nominal proceeds from warrant exercises

Financial Impact

The offering will provide capital for operations, but specific dollar amounts are not disclosed in the filing. The company previously registered a $300 million shelf offering.

cashdilutionequity

Risk Factors

  • Significant dilution to existing shareholders from new share issuance
  • Limited liquidity for pre-funded warrant holders due to no established trading market
  • Company has a history of operating losses and will require additional future funding

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-163919
Document: 0001193125-26-163919-index-headers.html0001193125-26-163919
Document: 0001193125-26-163919-index.html0001193125-26-163919
Document: 0001193125-26-163919.txt0001193125-26-163919
4 reports for SPRB
Performance horizon
Filters
Rows
Reports for SPRB — sortable, filterable
Type Now
May 13, 2026
4w ago
8-K
MIXED ★ 5/10
$57.55 $48.25▼ −16.16%▼ −15.00%$51.89 (−9.83%)
Apr 21, 2026
7w ago
424B5
NEUTRAL ★ 5/10
$52.36 $56.34▲ +7.60%▲ +7.55%$51.89 (−0.90%)
Apr 20, 2026
7w ago
424B5
NEUTRAL ★ 5/10
$51.69 $54.77▲ +5.96%▲ +4.87%$51.89 (+0.39%)
Mar 9, 2026
13w ago
8-K
MIXED ★ 6/10
$62.11 $60.95▼ −1.87%▼ −0.51%$51.89 (−16.45%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (48h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access